NO20073250L - Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser. - Google Patents

Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.

Info

Publication number
NO20073250L
NO20073250L NO20073250A NO20073250A NO20073250L NO 20073250 L NO20073250 L NO 20073250L NO 20073250 A NO20073250 A NO 20073250A NO 20073250 A NO20073250 A NO 20073250A NO 20073250 L NO20073250 L NO 20073250L
Authority
NO
Norway
Prior art keywords
liver
dioxides
isothiazole
modulating compounds
aniline derivatives
Prior art date
Application number
NO20073250A
Other languages
English (en)
Norwegian (no)
Inventor
Eva-Lotte Lindstedt Alstermark
Lanna Li
Patrik Holm
Pernilla Marie Sandberg
Kay Brickmann
Marianne Swanson
Anders Broo
Robert Judkins
Lars Weidolf
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20073250L publication Critical patent/NO20073250L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20073250A 2005-01-10 2007-06-25 Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser. NO20073250L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0500055A SE0500055D0 (sv) 2005-01-10 2005-01-10 Therapeutic agents 3
PCT/SE2006/000029 WO2006073366A1 (en) 2005-01-10 2006-01-09 Non-anilinic derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators

Publications (1)

Publication Number Publication Date
NO20073250L true NO20073250L (no) 2007-07-19

Family

ID=34132528

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073250A NO20073250L (no) 2005-01-10 2007-06-25 Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.

Country Status (19)

Country Link
US (2) US7723333B2 (zh)
EP (1) EP1838687A4 (zh)
JP (1) JP2008526844A (zh)
KR (1) KR20070094964A (zh)
CN (1) CN101137628A (zh)
AU (1) AU2006204164B2 (zh)
BR (1) BRPI0606391A2 (zh)
CA (1) CA2594404A1 (zh)
IL (1) IL184093A0 (zh)
MX (1) MX2007008405A (zh)
NO (1) NO20073250L (zh)
NZ (1) NZ556214A (zh)
RU (1) RU2415135C2 (zh)
SA (1) SA06270201B1 (zh)
SE (1) SE0500055D0 (zh)
TW (1) TW200804318A (zh)
UA (1) UA91992C2 (zh)
WO (1) WO2006073366A1 (zh)
ZA (1) ZA200705519B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526841A (ja) * 2005-01-10 2008-07-24 アストラゼネカ アクチボラグ 肝臓x受容体調節因子としてのイソチアゾール−3(2h)−オン1,1−ジオキシドのアニリン系誘導体
PE20121639A1 (es) * 2009-12-25 2012-12-02 Mochida Pharm Co Ltd Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40
EP2615094A4 (en) 2010-09-07 2013-09-18 Snu R&Db Foundation SESTERTERPEN COMPOUNDS AND THEIR USE
CA2882292C (en) 2012-08-13 2023-10-17 The Rockefeller University Treatment and diagnosis of melanoma
CA2939120A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
CA3178499A1 (en) 2015-06-30 2017-01-05 Eiger Group International, Inc. Use of clemizole, deuterated analogs of clemizole, or clemizole metabolites in treatment of an inflammatory condition
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
CN110105658B (zh) * 2019-04-04 2021-08-20 台州市黄岩聚丰机车有限公司 无卤阻燃聚丙烯电动自行车外饰件原材料
MX2022007164A (es) 2019-12-13 2022-09-12 Inspirna Inc Sales metálicas y usos de estas.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428956A (en) * 1980-12-29 1984-01-31 Merck & Co., Inc. 4-Hydroxy-5-substituted-3-(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
IE53068B1 (en) * 1981-06-15 1988-05-25 Merck & Co Inc Diamino isothiazole-1-oxides and -1,1-dioxides as gastic secretion inhibitors
US5411977A (en) * 1993-03-31 1995-05-02 The Dupont Merck Pharmaceutical Company Substituted 2,5-diaryl-4-isothiazolin-3-ones as antiinflammatory and antithrombotic agents
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
CN1304402A (zh) 1998-04-03 2001-07-18 三共株式会社 磺酰胺衍生物
ES2234300T3 (es) * 1998-10-08 2005-06-16 Smithkline Beecham Plc 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
CA2377999A1 (en) * 1999-07-08 2001-01-18 Tularik Inc Compositions and methods for raising hdl cholesterol levels
WO2001019831A1 (en) * 1999-09-10 2001-03-22 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
JP2001163786A (ja) 1999-09-30 2001-06-19 Sankyo Co Ltd スルホンアミド誘導体を含有する酵素阻害剤
GB0008264D0 (en) * 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds
EP1286964B1 (en) * 2000-05-11 2007-07-04 Consejo Superior de Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase gsk-3
ES2263681T3 (es) 2000-12-08 2006-12-16 Ortho-Mcneil Pharmaceutical, Inc. Compuestos de pirrolina indazolil-substituidos como inhibidores de la kinasa.
JP2005505595A (ja) 2001-10-12 2005-02-24 シェーリング コーポレイション Cxc−ケモカインレセプターアンタゴニストとしての3,4−二置換マレイミド化合物
ES2310622T3 (es) * 2001-12-19 2009-01-16 Bristol-Myers Squibb Company Compuestos heterociclicos condensados y analogos de los mismos, moduladores de la funcion de los receptores nucleares de hormonas.
GB0314302D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Novel compounds
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
WO2005035551A2 (en) 2003-10-08 2005-04-21 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
JP2008526841A (ja) * 2005-01-10 2008-07-24 アストラゼネカ アクチボラグ 肝臓x受容体調節因子としてのイソチアゾール−3(2h)−オン1,1−ジオキシドのアニリン系誘導体
SE0500056D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4
EP1838685A4 (en) * 2005-01-10 2010-01-27 Astrazeneca Ab DERIVATIVES OF ISOTHIAZOL-3- (2H) -THION-1,1-DIOXIDES AS LIVER-X RECEPTOR MODULATORS

Also Published As

Publication number Publication date
NZ556214A (en) 2010-07-30
AU2006204164B2 (en) 2009-11-05
SA06270201B1 (ar) 2009-12-16
BRPI0606391A2 (pt) 2009-11-17
SE0500055D0 (sv) 2005-01-10
ZA200705519B (en) 2008-08-27
AU2006204164A1 (en) 2006-07-13
CN101137628A (zh) 2008-03-05
RU2415135C2 (ru) 2011-03-27
US20100227847A1 (en) 2010-09-09
IL184093A0 (en) 2007-10-31
WO2006073366A1 (en) 2006-07-13
US7960380B2 (en) 2011-06-14
TW200804318A (en) 2008-01-16
KR20070094964A (ko) 2007-09-27
RU2007130151A (ru) 2009-02-20
JP2008526844A (ja) 2008-07-24
US20090005353A1 (en) 2009-01-01
EP1838687A4 (en) 2010-11-17
US7723333B2 (en) 2010-05-25
EP1838687A1 (en) 2007-10-03
CA2594404A1 (en) 2006-07-13
MX2007008405A (es) 2007-09-21
UA91992C2 (ru) 2010-09-27

Similar Documents

Publication Publication Date Title
NO20073250L (no) Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.
NO20060080L (no) Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer
NO20060081L (no) Pyrrol-2,5-dionderivater som lever X reseptormodulatorer
NO20073248L (no) Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer
EP2963037B1 (en) Novel pyrazole derivative
CN104302634B (zh) 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
CN104903301B (zh) 可用于调节IL‑12、IL‑23和/或IFNα的烷基酰胺取代的嘧啶化合物
CN107141309A (zh) 杂芳基化合物及其使用方法
CA2634676A1 (en) Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein cetp
CN107223125B (zh) sGC刺激剂
CA2650711A1 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
TW200900058A (en) N-(heteroaryl)-1-heteroaryl-1H-indole-2-carboxamide derivatives, their preparation and their therapeutic application
NO20071703L (no) Kinazolinderivater
CA2650625A1 (en) Formulations containing pyridazine compounds for treating neuroinflammatory diseases
BR112012008518A2 (pt) derivado heterocíclico, e, composição farmacêutica
NO20090328L (no) Nye forbindelser 385
BR112012027640A2 (pt) composto, composição farmacêutica uso de um composto, e, métodos de preparar uma composição farmacêutica, de inibir a função da 11beta-hidroxiesteroide desidrogenase do tipo 1 e de tratamento ou prevenção de um distúrbio
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
AR076300A1 (es) Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades.
WO2022010948A1 (en) Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases
SE0500056D0 (sv) Therapeutic agents 4
CN103402995A (zh) 新型吲哚、吲唑衍生物或其盐
AR038704A1 (es) Derivados de tiazol como antagonistas del receptor nyp
SE0500058D0 (sv) Therapeutic agents 5
NO20092400L (no) 4-(Heterocyclyl)Alkyl-N-(Arylsulfonyl) indole compounds and their use as 5-HT6 Ligands

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application